Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim to Prevent Chemotherapy Induced Thrombocytopenia in Ewing Sarcoma
NCT07048249Phase 1Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Rate of Chemotherapy Induced Thrombocytopenia at 52 weeks, Adverse Events at 52 weeks and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07048249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07048249.